Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxaneMarcin Kubeczko, Fara Brasó-Maristany, Sandra Cobo et al.|npj Breast Cancer|2026Cited by 0
Abstract PS5-01-23: Validation of the HER2DX Genomic Test in First-Line Advanced HER2-Positive Breast Cancer: Identifying Long-Term Responders to THPMarcin Kubeczko, F. Braso-Maritany, Sandra Cobo et al.|Clinical Cancer Research|2026Cited by 0
Abstract PS4-07-06: Independent validation of TNBCDX, a 15-gene genomic risk stratification tool for early-stage triple-negative breast cancerF. Brasó-Maristany, M. Alva, F. Pardo et al.|Clinical Cancer Research|2026Cited by 0